Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2006;99:528-536
Published online before print August 10, 2006, doi: 10.1161/01.RES.0000240147.49390.61
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
99/5/528    most recent
01.RES.0000240147.49390.61v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhai, P.
Right arrow Articles by Sadoshima, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhai, P.
Right arrow Articles by Sadoshima, J.
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Apoptosis
Right arrow Cell signalling/signal transduction
Right arrow Heart failure - basic studies
Right arrow Hypertrophy
(Circulation Research. 2006;99:528.)
© 2006 American Heart Association, Inc.


Integrative Physiology

An Angiotensin II Type 1 Receptor Mutant Lacking Epidermal Growth Factor Receptor Transactivation Does Not Induce Angiotensin II–Mediated Cardiac Hypertrophy

Peiyong Zhai*, Jonathan Galeotti*, Jing Liu, Eric Holle, Xianzhong Yu, Thomas Wagner, Junichi Sadoshima

From the Cardiovascular Research Institute (P.Z., J.G., J.L., J.S.), Department of Cell Biology and Molecular Medicine, University of Medicine & Dentistry of New Jersey, New Jersey Medical School, Newark; and Oncology Research Institute (E.H., X.Y., T.W.), Greenville, SC.

Correspondence to Junichi Sadoshima, MD, PhD, Cardiovascular Research Institute, UMDNJ, New Jersey Medical School, 185 South Orange Ave, MSB G609, Newark, NJ 07103. E-mail sadoshju{at}umdnj.edu

We have shown previously that tyrosine 319 in a conserved YIPP motif in the C terminus of angiotensin II (Ang II) type 1 receptors (AT1Rs) is essential for transactivation of epidermal growth factor receptor (EGFR) in vitro. We hypothesized that the signaling mechanism mediated through the specific amino acid sequence in the G protein–coupled receptor plays an important role in mediating cardiac hypertrophy in vivo. Transgenic mice with cardiac-specific overexpression of wild-type AT1R (Tg-WT) and an AT1R with a mutation in the YIPP motif (Tg-Y319F) were studied. Tg-Y319F mice developed no significant cardiac hypertrophy, in contrast to the significant development of hypertrophy in Tg-WT mice. Expression of fetal-type genes, such as atrial natriuretic factor, was also significantly lower in Tg-Y319F than in Tg-WT mice. Infusion of Ang II caused an enhancement of hypertrophy in Tg-WT mice but failed to induce hypertrophy in Tg-Y319F mice. Left ventricular myocardium in Tg-Y319F mice developed significantly less apoptosis and fibrosis than that in Tg-WT mice. EGFR phosphorylation was significantly inhibited in Tg-Y319F mice, confirming that EGFR was not activated in Tg-Y319F mouse hearts. In contrast, activation/phosphorylation of protein kinase C, STAT3, extracellular signal-regulated kinase, and Akt and translocation of G{alpha}q/11 to the cytosolic fraction were maintained in Tg-Y319F hearts. Furthermore, a genetic cross between Tg-WT and transgenic mice with cardiac-specific overexpression of dominant negative EGFR mimicked the phenotype of Tg-Y319F mice. In conclusion, overexpression of AT1-Y319F in cardiac myocytes diminished EGFR transactivation and inhibited a pathological form of cardiac hypertrophy. The YIPP motif in the AT1R plays an important role in mediating cardiac hypertrophy in vivo.


Key Words: AT1 receptor • YIPP motif • transactivation • EGFR • hypertrophy




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. J. Gelpi, S. Gao, P. Zhai, L. Yan, C. Hong, L. M. A. Danridge, H. Ge, Y. Maejima, M. Donato, M. Yokota, et al.
Genetic inhibition of calcineurin induces diastolic dysfunction in mice with chronic pressure overload
Am J Physiol Heart Circ Physiol, November 1, 2009; 297(5): H1814 - H1819.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. G. Tilley, I.-M. Kim, P. A. Patel, J. D. Violin, and H. A. Rockman
{beta}-Arrestin Mediates {beta}1-Adrenergic Receptor-Epidermal Growth Factor Receptor Interaction and Downstream Signaling
J. Biol. Chem., July 24, 2009; 284(30): 20375 - 20386.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. Cai, F.-F. Yi, L. Yang, D.-F. Shen, Q. Yang, A. Li, A. K. Ghosh, Z.-Y. Bian, L. Yan, Q.-Z. Tang, et al.
Targeted Expression of Receptor-Associated Late Transducer Inhibits Maladaptive Hypertrophy via Blocking Epidermal Growth Factor Receptor Signaling
Hypertension, March 1, 2009; 53(3): 539 - 548.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. F.X. Ainscough, M. J. Drinkhill, A. Sedo, N. A. Turner, D. A. Brooke, A. J. Balmforth, and S. G. Ball
Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction
Cardiovasc Res, February 15, 2009; 81(3): 592 - 600.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
V. Rajagopalan, I. H. Zucker, J. A. Jones, M. Carlson, and Y. J. Ma
Cardiac ErbB-1/ErbB-2 mutant expression in young adult mice leads to cardiac dysfunction
Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H543 - H554.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
M. V. Arcidiacono, T. Sato, D. Alvarez-Hernandez, J. Yang, M. Tokumoto, I. Gonzalez-Suarez, Y. Lu, Y. Tominaga, J. Cannata-Andia, E. Slatopolsky, et al.
EGFR Activation Increases Parathyroid Hyperplasia and Calcitriol Resistance in Kidney Disease
J. Am. Soc. Nephrol., February 1, 2008; 19(2): 310 - 320.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
D. Frank, C. Kuhn, B. Brors, C. Hanselmann, M. Ludde, H. A. Katus, and N. Frey
Gene Expression Pattern in Biomechanically Stretched Cardiomyocytes: Evidence for a Stretch-Specific Gene Program
Hypertension, February 1, 2008; 51(2): 309 - 318.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Mogi, M. Iwai, and M. Horiuchi
Emerging Concepts of Regulation of Angiotensin II Receptors: New Players and Targets for Traditional Receptors
Arterioscler Thromb Vasc Biol, December 1, 2007; 27(12): 2532 - 2539.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Zhai, S. Gao, E. Holle, X. Yu, A. Yatani, T. Wagner, and J. Sadoshima
Glycogen Synthase Kinase-3{alpha} Reduces Cardiac Growth and Pressure Overload-induced Cardiac Hypertrophy by Inhibition of Extracellular Signal-regulated Kinases
J. Biol. Chem., November 9, 2007; 282(45): 33181 - 33191.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
T. L. Reudelhuber, K. E. Bernstein, and P. Delafontaine
Is Angiotensin II a Direct Mediator of Left Ventricular Hypertrophy?: Time for Another Look
Hypertension, June 1, 2007; 49(6): 1196 - 1201.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. C. Schaub and M. A. Hefti
The PGE2-Stat3 connection in cardiac hypertrophy
Cardiovasc Res, January 1, 2007; 73(1): 3 - 5.
[Full Text] [PDF]